Yang Nanmu, Zhou Jinxue, Li Qingjun, Han Feng, Yu Zujiang
1Department of Infectious Disease, The First Affiliated Hospital of Zhengzhou University, No. 1, Jianshe East Road, Zhengzhou, 450052 Henan China.
2Department of Hepatopancreatobiliary Surgery, Henan Cancer Hospital, No. 127, Dongming Road, Zhengzhou, 450008 Henan China.
Cancer Cell Int. 2019 Feb 20;19:38. doi: 10.1186/s12935-019-0756-7. eCollection 2019.
The aim of this research was to investigate the mechanism of miR-96 affecting hepatocellular carcinoma (HCC).
mRNA and protein expression was detected by qRT-PCR and Western blot, respectively. HepG2 cells were transfected and grouped as follows: miR-NC group, miR-mimics group, NC + Vector group, mimics + Vector group, mimics + FOXO1 group. Luciferase reporter assay was performed. MTT and Transwell assay was conducted. In vivo studies by nude mice were performed. Immunohistochemistry and immunofluorescence was executed.
Up-regulated miR-96 and down-regulated FOXO1 was found in tumor tissues and HepG2 cells (< 0.01). FOXO1 was directly suppressed by miR-96. Compared with NC + Vector group, mimics + Vector group has higher OD495 value ( < 0.05), higher migration and invasion cells ( < 0.01), larger transplanted tumor volume ( < 0.01), lower FOXO1 positive cell numbers ( < 0.01), higher p-AKT and p-GSK-3β expression ( < 0.01), lower p-β-catenin expression ( < 0.01), more β-catenin expression in the nucleus ( < 0.01). Compared with mimics + Vector group, mimics + FOXO1 group has lower OD495 value ( < 0.05), lower migration and invasion cells (P < 0.01), smaller transplanted tumor volume ( < 0.01), higher FOXO1 positive cells ( < 0.01), lower p-AKT and p-GSK-3β expression ( < 0.01), higher p-β-catenin expression ( < 0.01), less β-catenin expression in the nucleus ( < 0.01).
miR-96 exerts carcinogenic effect by activating AKT/GSK-3β/β-catenin signaling pathway through targeting inhibition of FOXO1 in HCC.
本研究旨在探讨miR-96影响肝细胞癌(HCC)的机制。
分别采用qRT-PCR和蛋白质免疫印迹法检测mRNA和蛋白质表达。对HepG2细胞进行转染并分组如下:miR-NC组、miR-模拟物组、NC+载体组、模拟物+载体组、模拟物+FOXO1组。进行荧光素酶报告基因检测。开展MTT和Transwell检测。通过裸鼠进行体内研究。进行免疫组织化学和免疫荧光检测。
在肿瘤组织和HepG2细胞中发现miR-96上调而FOXO1下调(<0.01)。FOXO1受到miR-96的直接抑制。与NC+载体组相比,模拟物+载体组具有更高的OD495值(<0.05)、更多的迁移和侵袭细胞(<0.01)、更大的移植瘤体积(<0.01)、更低的FOXO1阳性细胞数(<0.01)、更高的p-AKT和p-GSK-3β表达(<0.01)、更低的p-β-连环蛋白表达(<0.01)、更多的β-连环蛋白在细胞核中的表达(<0.01)。与模拟物+载体组相比,模拟物+FOXO1组具有更低的OD495值(<0.05)、更低的迁移和侵袭细胞(P<0.01)、更小的移植瘤体积(<0.01)、更高的FOXO1阳性细胞(<0.01)、更低的p-AKT和p-GSK-3β表达(<0.01)、更高的p-β-连环蛋白表达(<0.01)、更少的β-连环蛋白在细胞核中的表达(<0.01)。
miR-96在肝癌中通过靶向抑制FOXO1激活AKT/GSK-3β/β-连环蛋白信号通路发挥致癌作用。